Cue Biopharma (CUE) stock price, chart and financials
Price chart
Financials
- Revenue (quarter)
- $7.9M
- Revenue growth (year over year)
- +166.66%
- Gross margin
- 100.00%
- Net income (quarter)
- −$153.1M
- Net income growth (year over year)
- −1704.61%
- Net margin
- −435.82%
- Return on equity
- −1603.48%
- EPS (trailing twelve months)
- −$29.46
- Book value per share
- $0.44
- Price to book
- 61.54
- Debt to assets
- 92.48%
Company profile
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
Frequently asked questions
Is Cue Biopharma (CUE) profitable?
No. Cue Biopharma reported a net loss of $164.1M over the trailing twelve months.
How much revenue does Cue Biopharma (CUE) make?
Cue Biopharma generated $37.7M in revenue over the trailing twelve months, up 166.66% year over year.
How do I buy stock in Cue Biopharma (CUE)?
CUE trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.
Quotes and charts are not real-time and must not be relied on for trade decisions or valuation.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.